10/2/98 infections of the upper respiratory tract cynthia l. gibert, m.d. washington va medical...
TRANSCRIPT
10/2/98
Infections of the
Upper Respiratory Tract
Cynthia L. Gibert, M.D.
Washington VA Medical Center
10/2/98
Upper Respiratory Infections
• Upper respiratory tract infections are the most common human affliction.
• Major share of time lost from work and school.
• Most common cause of antibiotic abuse.
10/2/98
Spanish Flu Pandemic of 1918
• Sept. - Nov. 1918
• 20-40 million deaths
• More Americans died than in the WWI, WW2, Korea, Vietnam
• 1st case Camp Fuston, Kansas - 3/4/18
10/2/98
Influenza A Pandemics
1918 - 1919 Spanish H1N1
1957 - 1958 Asian H2N2
1968 - 1969 Hong Kong H3N2
10/2/98
Epidemiologic Characteristics
• Pandemics Worldwide - antigenic shift• Epidemics Local - antigenic drift• Endemic Sporadic• Seasonal Winter months - abrupt• Age Infection: children > adults
Mortality: adults > children
10/2/98
Pathogenesis
• Virus replication: 24 - 72 hours
• Virus excretion: 3 - 7 days
• Antibodies to HA, NA subtypes
10/2/98
Secondary Bacterial Pathogens
• S. pneumoniae
• H. influenzae
• S. aureus - Toxin Shock Syndrome
10/2/98
Reye’s Syndrome
• Post influenza B
• Encephalopathy
• Hepatic dysfunction
• Elevate NH3, LFTs, CPK
10/2/98
Influenza Vaccine
Trivalent vaccine
• A/Beijing/262/95-like (H1N1)
• A/Sydney/5/97-like (H3N2)
• B/Harbin/07/94
10/2/98
Indications for Vaccine
• Elderly (age>65)
• High-risk*
• Household contacts
• Health-care personnel
• Pregnant women after 14th week
High-risk: institutionalized, chronic heart or lung disease, diabetes,
renal dysfunction, immunosuppressed, children on aspirin
10/2/98
Influenza Vaccine
• Timing: October - Mid-November
• Duration of immunity: start 1-2 weeks end 4-6 months
10/2/98
Diagnosis
• Viral culture - tissue culture
• Fluorescent-labeled murine monoclonal Ab - shell viral cell culture - viral Ag
• PCR
• CF - at onset and 2 weeks
4-fold-rise in Ab titre
10/2/98
Treatment of Influenza A
Amantadine or rimantadine within 48 hours
decreases fever and severity
• Use in elderly or high risk
• Hospitalized persons
• Healthy adults
10/2/98
Prophylaxis of Influenza A
• Control of outbreaks in institutions
• Adjunct to late vaccination
• Immunodeficient - AIDS
• Vaccine contraindicated
• Home caregivers of high risk
10/2/98
Epiglottitis - Acute Supraglottitis
• A rapidly progressive and potentially fatal disease that must be recognized immediately.
10/2/98
Epiglottitis
• Epidemiology: – most common in children 3-7 yrs.– decreased incidence because of Hib conjugate
vaccine-stable rate in adults
• Rate:– 1 in 1000-2000 pediatric admissions– 1 in 100,000 adult admissions
10/2/98
Differential Diagnosis of a Sore Throat
• Peritonsillar abscess– sore throat, drooling, hoarseness, trismus, asymmetric tonsillar
enlargement
• Epiglottitis – Children: high fever, toxic, drooling, absence of cough – Adult: severe sore throat, dyshagia, fever
• Infectious mononucleosis– tonsillar enlargement, exudative tonsillitis, pharyngeal inflammation,
lymphadenopathy, splenomegaly, maculopapular rashes, petechial anathema
• Parapharyngeal space infection– neck swelling after a sore throat
10/2/98
Epiglottitis - Pathogenesis• Haemophilus influenzae type b,
S. pneumoniae, S. aureus, H. influenzae type non-b, H. parainfluenzae
• Inflammation and edema of the epiglottis, arytenoids, arytenoepiglottic folds, subglottic area
• Epiglottis pulled down into larynx and occludes the airway
10/2/98
Epiglottitis Clinical Manifestations
• Abrupt onset - sore throat, fever, toxicity dysphagia, drooling, stridor, chest wall retractions
• Beefy-red epiglottis
• Inspiratory stridor and expiratory ronchi
• Adults: muffled voice, drooling
10/2/98
Epiglottitis - Diagnosis
• Visualization of epiglottis - “cherry red”
• Laternal neck x-rays: “thumb sign”
• WBC count > 15,000 left shift
• Blood cultures
10/2/98
Differential Diagnosis
• Viral croup - barking cough, less abrupt, less toxic
• Bacterial tracheitis - S. aureus, H. influenzae, Strept., diphtheria
• Aspiration of a foreign body
10/2/98
Therapy
• Adequate airway - nasotracheal intubation
• Adults - close observation
• Antibiotics – cefuroxime, ceftriaxone– ampicillin resistance - up to 30%– chloramphenicol
? Corticosteroids - reduce postintubation inflammation
10/2/98
Prevention
Rifampin - 20 mg/kg for 4 days
• All household contacts if children under 4
• Daycare and nursery school contacts
• Patient before discharge
10/2/98
Sinusitis - Clinical Findings
• Viral URI, fever (50%), purulent nasal discharge, swelling, facial pain worse on percussion, headache, nasal obstruction, loss of smell
• Children: facial pain, swelling, malodorous breath (50%), cough (80%), nasal discharge (76%), fever (63%), sore throat (23%)
10/2/98
Specific Clinical Criteria
• Maxillary toothache, colored nasal discharge, poor response to nasal decongestants, abnormal transillumination, purulent secretions, cough > 7 days
10/2/98
Diagnosis
• Nasal swabs not helpful• Transillumination of maxillary and frontal sinuses• Sinus x-rays: air-fluid level, complete opacity,
mucosal thickening• CT scan not indicated - unless chronic infection,
immunocompromised, suspected intracranial or orbital complication
• Direct sinus aspiration
10/2/98
Factors that Predispose to Sinusitis
• Impaired mucociliary function
• Obstruction of sinus ostia
• Immune defects
• Increased risk of microbial invasion
10/2/98
Microbial Causes of Acute Maxillary Sinusitis
PREVALENCE MEAN (RANGE)
Adults Children
MICROBIAL AGENT (Bacteria) (%) (%)
Streptococcus pneumoniae 31 (20-35) 36
Haemophilus influenzae 21 (6-26) 23
(nonencapsulated)
S. pneumoniae and H. influenzae 5 (1-9) --
Anaerobes (Bacteroides, Fusobacterium, 6 (0-10) --
Peptostreptococcus, Veillonella)
Staphylococcus aureus 4 (0-8) --
Streptococcus pyogenes 2 (1-3) 2
Branhamella (Moraxella) catarrhalis 2 19
Gram-negative bacteria 9 (0-24) 2
10/2/98
Microbial Causes of Acute Maxillary Sinusitis
PREVALENCE MEAN (RANGE)
Adults Children
MICROBIAL AGENT (%) (%)
Viruses
Rhinovirus 15 --
Influenza virus 5 --
Parainfluenza virus 3 2
Adenovirus -- 2
10/2/98
Decongestants
• Oxymetazoline HCL - TID for 48-72 hours
• Pseudoephedrine HCL - only if allergic component
• Nasal steroids for 2-3 weeks
10/2/98
Therapy
Empiric antibiotics for 10 days
• Amoxicillin/ampicillin
• TMP/SMX
• Cephalosporin - cefaclor, cefuroxime
• Azithromycin, clarithromycin
10/2/98
Chronic Sinusitis
• Symptoms for > 3 months
Allergies, inadequately treated
• Aerobes and anaerobes
• ENT evaluation for endoscopy or CT
• Antibiotics for 3-4 weeks
10/2/98
Caveat
• Frontal sinusitis with tenderness and headache - thin barrier to CNS
• Treat 10-14 days
10/2/98
Ethmoid and Sphenoid Sinusitis
• Ethmoid sinusitis: edema of eyelids, tearing,retroorbital pain, proptosis
• Sphenoid sinusitis: intractable headache, hypo/hyperesthesia of ophthalmic or maxillary branches of trigeminal n. (30%)
10/2/98
Cavernous Sinus Thrombosis
• Depressed mental status
• Meningeal irritation
• Ptosis, chemosis
• Proptopsis
• C.N. palsies - III, IV, VI
10/2/98
Intracranial Complications of Sinusitis
Complication Clinical Signs• Meningitis Headache, fever, stiff neck
lethargy, rapid death• Osteomyelitis Pott’s puffy tumor• Epidural abscess Headache, fever• Subdural empyema Headache, seizures
hemiplegia, rapid death• Cerebral abscess Convulsions, headache,
personality change• Venous sinus thrombosis Picket-fence fever, rapid death• Cavernous sinus Orbital edema, ocular palsies
10/2/98
The Common Cold
• Hippocrates: – rejected bleeding
• Pliny the Younger: – kiss the hairy muzzle of a mouse
• Ben Franklin: – not from exposure to cold/dampness; – close contact
10/2/98
Epidemiology
• 65 million colds per year
• 150 million days of restricted activity
• 24 million medical visits
• 18 million days lost from work
• 22 million days missed from school
10/2/98
VirologyOver 200 viruses
Virus type SerotypesAndenoviruses 41
Coronaviruses 2
Influenza viruses 3
Parainfluenza viruses 4
Respiratory syncytial virus 1
Rhinoviruses 100+
Enteroviruses 60+
10/2/98
Seasonal Variation
• May-Aug - Enteroviruses
• Sept-Dec - Mycoplasma, Rhinoviruses,
Parainf. 1+2, RSV
• Jan-Feb - Adenoviruses, Influenza, Coronaviruses
• Mar-Apr - Parainf. 3, Rhinoviruses
10/2/98
Transmission
• Direct contact with infected secretions
• Hand - to - hand
• Hand - to environmental surface - to hand
• Spread by aerosoles
10/2/98
Pathogenesis
• Incubation period 1 - 4 days
• Begins in posterior pharynx
• Viral shedding days 3 - 4
10/2/98
Clinical Presentation
Dry, scratchy, sore throat
Sneezing, nasal stuffiness, rhinorrhea
Malaise, myalgia, headache
Hoarseness, cough, low grade fever
10/2/98
Complications
• Bacterial superinfection– Otitis media– Sinusitis– S. pneumoniae, H. influenzae, B. catarrhalis
• Guillain-Barre Syndrome
• Asthma attacks
10/2/98
Management
• Throat culture, rapid Ag detection for group A strep
• Diagnosis of influenza A, RSV
10/2/98
Use of Antibiotics
• No benefit
• Do not reduce bacterial complications
• Emergence of resistant organisms
10/2/98
Aspirin and Influenza
• Aspirin - prolonged excretion of rhinoviruses, influenza virus
• Children - aspirin associated with Reye’s syndrome